Podcasts about orbita

Tre anni dopo l'insediamento di Giorgia Meloni a Palazzo Chigi, il governo attuale è il più stabile nella storia recente del Paese. Lo spread è sceso e, mentre l'Europa sembra essere sempre più debole, l'Italia si presenta come un'oasi di stabilità. Cosa aspettarsi dal futuro per l'economia del nostro Paese, tra le sfide poste da intelligenza artificiale, calo demografico e cambiamento climatico? Ne parlano in questa puntata, registrata allo spazio Orbita di Triennale, Guido Maria Brera e Raffaele Coriglione insieme a Chiara Albanese e Tommaso Ebhardt di Bloomberg News e host di “Quello che i soldi non dicono”. Learn more about your ad choices. Visit megaphone.fm/adchoices

Come mai l'Italia gode di un momento di fiducia finanziaria, e come valutare e posizionarsi per potenziali rischi? Questa puntata, in cui Chiara Albanese e Tommaso Ebhardt, host di Quello che i soldi non dicono, dialogano con Guido Maria Brera e Raffaele Coriglione, host del podcast Black Box, è stata registrata live il 29 ottobre 2025 in Triennale Milano, durante “Business Corner: Quello che i soldi non dicono e CEO Insight by Actually”, un evento della serie di Orbita, in collaborazione con Chora e Will. Learn more about your ad choices. Visit megaphone.fm/adchoices

Guardarsi in una foto e scoprirsi sovrappeso: è successo a Dario Bressanini, chimico e divulgatore scientifico, che - partendo dalla sua esperienza - nel suo libro "La dieta termodinamica" racconta i fondamenti scientifici dell'aumento di peso e della perdita di peso: perché ingrassiamo, perché dimagriamo, come funziona il nostro corpo. Questo episodio è stato realizzato in occasione di Orbita, la rassegna di eventi dal vivo di Chora & Will che si tiene ogni mercoledì sera a Milano, nello spazio Voce in Triennale. Scopri come partecipare su orbita.chorawill.com/

Nel The Essential di martedì 4 novembre, Chiara Piotto parla di: 00:00 lo scandalo delle bambole pedopornografiche di Shein in Francia; 05:25 la torre dei Conti semi-crollata a Roma; 07:30 la liberazione della 19enne britannica incinta Bella Culley dal carcere in Georgia, mentre Alberto Trentini resta in carcere dopo quasi un anno in Venezuela. Questo episodio è supportato da ⁠Edenred⁠: le soluzioni welfare per la crescita delle aziende e il benessere dei dipendenti Mercoledì 5 novembre dalle 19 The Essential sarà live alla Triennale di Milano, all'interno della rassegna "Orbita" di Will & Chora Media. Chiara Piotto parlerà di quanto è difficile diventare genitori in Italia e delle best practice per la natalità in Italia e in Europa, insieme alla deputata PD Lia Quartapelle e alla politologa Flavia Restivo, autrice di "Gli svedesi lo fanno meglio". L'evento è aperto al pubblico! Potete iscrivervi a questo link ⁠⁠https://orbita.chorawill.com/ Firma la proposta di legge di iniziativa popolare per chiedere una legge sul voto fuorisede: ⁠⁠⁠https://shor.by/zQ5D⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

Nell'episodio di lunedì 3 novembre, Chiara Piotto parla di: 00:00 l'accoltellamento di 10 persone su un treno vicino a Londra; 04:50 l'elezione per il sindaco di New York con Zohran Mamdani in testa; 07:50 la campagna per rendere gratuito il congelamento degli ovociti in Italia come in Francia. Questo episodio è supportato da Edenred: le soluzioni welfare per la crescita delle aziende e il benessere dei dipendenti Mercoledì 5 novembre dalle 19 The Essential sarà live alla Triennale di Milano, all'interno della rassegna "Orbita" di Will & Chora Media. Chiara Piotto parlerà di quanto è difficile diventare genitori in Italia e delle best practice per la natalità in Italia e in Europa, insieme alla deputata PD Lia Quartapelle e alla politologa Flavia Restivo, autrice di "Gli svedesi lo fanno meglio". L'evento è aperto al pubblico! Potete iscrivervi a questo link ⁠https://orbita.chorawill.com/ Firma la proposta di legge di iniziativa popolare per chiedere una legge sul voto fuorisede: ⁠⁠https://shor.by/zQ5D⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

Nel The Essential di venerdì 31 ottobre, Chiara Piotto parla di: 00:00 Donald Trump ha annunciato che gli USA riprenderanno i test nucleari, sospesi dal '92; 04:00 perché il Governo andrà avanti sul ponte sullo Stretto di Messina, nonostante il parere negativo della Corte dei Conti; 07:15 perché guardare i film horror può aiutarvi a combattere l'ansia Mercoledì 5 novembre dalle 19 The Essential sarà live alla Triennale di Milano, all'interno della rassegna "Orbita" di Will & Chora Media. Chiara Piotto parlerà di quanto è difficile diventare genitori in Italia e delle best practice per la natalità in Italia e in Europa, insieme alla deputata PD Lia Quartapelle e alla politologa Flavia Restivo, autrice di "Gli svedesi lo fanno meglio". L'evento è aperto al pubblico! Potete iscrivervi a questo link https://orbita.chorawill.com/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Usa INCOGNI con uno sconto del 60% sul primo anno: https://incogni.com/astroviktor

Con Simonetta Di Pippo, Professor of Practice di Space Economy e Direttore dello Space Economy Evolution Lab (SEE Lab), in SDA Bocconi, esploriamo il tema della difesa planetaria e della sicurezza dello spazio. Dalla minaccia degli asteroidi ai detriti orbitanti, fino al futuro delle megacostellazioni e alla democratizzazione dell'accesso allo spazio: un viaggio tra scienza, tecnologia e diplomazia orbitale.Ospite: Simonetta Di Pippo Redazione: Elisa Baioni, Clarissa Esposti, Manuela Gialanella, Diego Martin, Matteo Melchiori, Giuseppe Molle, Alex Ordiner, Dasara Shullani, Matilde Spagnolo, Cristiano Ursella, Chiara Vitaloni, Enrico Zabeo Altri riferimenti: [https://www.sdabocconi.it/en/faculty-research/research/technology-innovation-and-transition-knowledge-platform/see-lab Space Economy Evolution Lab (SEE Lab)] Musiche: [https://www.epidemicsound.com/ Epidemic Sound] Seguiteci sui profili social del CICAP: Facebook: https://www.facebook.com/@cicap.org Instagram: https://www.instagram.com/cicap_it/ Newsletter: https://eepurl.com/ihPeWL

Nel 2012 un ragazzo italiano di vent'anni viene acclamato dai giornali di tutto il mondo come il “nuovo Zuckerberg”. La sua innovazione è un social network rivoluzionario, una start up con utili di decine di milioni di euro, decine di dipendenti e una capitalizzazione di oltre un miliardo. Ma il sogno finisce già prima di cominciare perché dietro quella storia non c'è nulla: nessuna app, nessuna azienda, solo un caso mediatico costruito sul vuoto. La genialità è stata quella di aver creato un unicorno gonfiabile. Questa puntata, in cui Gian Luca Comandini, host di Out of the Box, dialoga con Nicolas Nati, fondatore di akka.app, è stata registrata live il 24 settembre 2025 in Triennale Milano, durante “Business Corner: Out of the Box e Don Chisciotte”, un evento della serie di Orbita, in collaborazione con Chora e Will. Learn more about your ad choices. Visit megaphone.fm/adchoices

▼ Follow Nicksher Music: » Spotify Playlist: https://open.spotify.com/playlist/4dI7kNNcEGQ8MSGLYVh39T?si=Zg1yjJAHTASjK7xa5S-Lew » SoundCloud: https://soundcloud.com/nickshermusic » YouTube: https://www.youtube.com/channel/UCcTF27v-cpxlBfLdQODpFTw » Beatport: https://beatport.com/label/nicksher-music/57468 » VK: https://vk.com/club123650463 » Instagram: https://www.instagram.com/nickshermusic/ --- ▼ Follow Rasti'sLove: SoundCloud: https://soundcloud.com/user-983152104-874597905 VK: https://vk.com/rasti_s_love

Detriti spaziali, orbite impossibili, jetpack hollywoodiani e sacrifici inutili: in questo episodio analizziamo la scienza (e le licenze narrative) del film Gravity.

441-1-286-Z-27rod - 1631 - ¿Podríamos interceptar a 3I/ATLAS utilizando la sonda JUNO que actualmente orbita a Júpiter? La respuesta es: Sí Universo de Misterios tiene reservado el derecho de admisión y publicación de comentarios. Generalmente, los comentarios anónimos no serán publicados. Si hace comentarios con afirmaciones dudosas, arguméntelas aportando enlaces a fuentes fiables (este muro NO es una red social). En caso de no respaldar su comentario como se indica en la caja de descripción del episodio, su comentario podrá ser no publicado. Contacto con Universo de Misterios: universodemisteriospodcast@gmail.com La imagen de la miniatura que ilustra este episodio ha sido creada con la ayuda de una Inteligencia Artificial. Puedes hacerte Fan de Universo de Misterios y apoyarlo económicamente obteniendo acceso a todos los episodios cerrados, sin publicidad, desde 1,99 €. Aunque a algunas personas, a veces, puede proporcionar una falsa sensación de alivio, la ignorancia nunca es deseable. Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

Nei weekend potete immaginarla a casa sul suo divano mentre guarda la Formula Uno. Ma quella per l'automobilismo è solo una delle tante altre passioni di Francesca Michielin, che oltre alla musica ama l'atletica e passare del tempo nel lavoratorio di ceramica, creando oggetti con le sue mani. In questa intervista realizzata nello spazio di Orbita in Triennale Milano, Francesca Michielin racconta a Silvia Nucini tutte le sue passioni, di quella volta che le hanno tolto il malocchio e di come, in un mondo che va sempre più veloce, sia riuscita a rallentare.

In questa puntata speciale di Black Box registrata dal vivo a Orbita, la rassegna di incontri organizzata in Triennale da Chora Media con il sostegno di UniSalute, Guido Brera dialoga con Riccardo Quagliotti, Portfolio manager di Kairos Partners SGR, sul tema della longevity, su come la ricerca scientifica e l'intelligenza artificiale ci allungheranno la vita e sull'impatto che questo avrà sulla nostra società. Per saperne di più clicca qui. Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us a textDr. Bobby unpacks the surge of health hype—from red light therapy to NAD⁺ boosters—and empowers listeners to stay curious yet skeptical using science-backed tools and critical thinking.Are claims like “boost your mitochondria” or “natural detox” real breakthroughs—or today's version of snake oil? Dr. Bobby explores why health hype is everywhere, why we're vulnerable to it, and how to sift compelling theories from proven treatments. He outlines examples of widely accepted beliefs that ultimately didn't hold up to rigorous scrutiny. Inserting stents to open clogged arteries seemed sensible, but studies like the COURAGE and ORBITA trials found no added benefit over medical management (NEJM). Dr. Bobby then turns to newer fads. Claims around NAD⁺ boosters (like NMN or NR), red light therapy, PRP for knee pain, and hydrogen water often rely on plausible-sounding mechanisms or mouse studies—but currently lack human RCTs to back them up. While these ideas may sound promising, human trials are either missing or preliminary.Why does this hype persist? Financial incentives are everywhere: the U.S. spends over $5 trillion annually on health, and the supplement market alone is worth $150 billion. Influencers, professionals, and even well-meaning providers may promote approaches they financially benefit from. As patients, we're often eager for solutions to symptoms like fatigue or anxiety—especially when conventional medicine doesn't have a satisfying answer. This opens the door for pseudoscience, placebo effects, and the viral spread of misinformation.To navigate this environment, Dr. Bobby outlines seven action steps. First, demand human evidence: ask if a treatment has been tested in RCTs, replicated, and proven in diverse populations. He recommends Examine.com for non-biased supplement research and revisiting his episode on evaluating health headlines (#22). Second, follow the money—financial conflicts should raise your skepticism. Third, be alert to hypey language like “miracle cure” or “doctor secrets”—phrases designed to manipulate, not inform. Fourth, understand the placebo effect, especially with vague symptoms. Fifth, ask  questions: “Compared to what?” “In whom?” “For how long?” “With what risks?” These shift the focus from excitement to real evaluation. Sixth, adopt what Dr. Bobby calls the mindset of a curious skeptic—open to ideas, but insistent on evidence. Finally, he urges listeners to consult evidence-literate doctors who will explore with you, both mainstream and emerging treatments with a critical eye—see episode #20 for more on choosing the right provider.Takeaways: Ask, “Has this been tested in people?” before jumping on a health trend. Beware buzzwords and financial conflicts—science, not sales, should guide your decisions. Embrace curiosity, but anchor it in real-world evidence to truly live long and well.

Arroz de marisco, marteladas e passarada.

Maracanà con Marco Piccari Ospite: Ceccarini:" David è un giocatore della Juve. Il sogno è Tonali. Calha ha creato un problema, la squadra è divisa. Inter investimenti di prospettiva. Nunez ancora in orbita Napoli.

Maracanà con Marco Piccari Ospite: Ceccarini:" David è un giocatore della Juve. Il sogno è Tonali. Calha ha creato un problema, la squadra è divisa. Inter investimenti di prospettiva. Nunez ancora in orbita Napoli.

Il primo appuntamento con Venere dei giapponesi è stato un mezzo disastro. Arrivati puntuali, nel momento cruciale hanno fatto fiasco, perdendo la loro missione Akatsuki e trovandola in un'orbita completamente diversa e persino problematica. Per tornare a Venere ci sono voluti cinque anni, ma poteva andare molto peggio se non fosse intervenuto un giovane italiano che non la missione non c'entrava nulla, ma si trovava nel posto giusto al momento giusto. Lui è Stefano Campagnola, lavora alla Nasa e lo conosceremo in questa puntata di Houston. Musiche: “Contagion”, Scott Buckley; “Sneaky Snooper”, instrumental brother

In this podcast, Dr. Valentin Fuster discusses a groundbreaking study from the Orbiter 2 trial, which explores how dobutamine stress echocardiography (DSE) can predict the efficacy of percutaneous coronary intervention (PCI) in relieving angina in patients with stable coronary artery disease. The study reveals that the degree of ischemia, as measured by DSE, is strongly correlated with improvement in symptoms, offering new insights into patient selection for PCI treatment.

O wyróżnionej prestiżową Nagrodą Bookera powieści Samanthy Harvey "Orbita". Sześcioro astronautów krąży wokół Ziemi na pokładzie statku kosmicznego, a oddalenie pozwala im głębiej zrozumieć własne przywiązanie do Ziemi, jej znaczenie i sytuację całej ludzkości. 

La Terra orbita attorno al Sole una volta all'anno. Questo movimento, chiamato moto di rivoluzione, avviene lungo un'orbita ellittica e richiede circa 365 giorni, 5 ore, 48 minuti e 46 secondi per completarsi. Questo periodo è noto come anno solare.A causa delle circa 6 ore extra ogni anno, ogni 4 anni si aggiunge un giorno al calendario, creando l'anno bisestile. Questo aggiustamento mantiene il calendario in sincronia con le stagioni.Esiste anche l'anno siderale, che misura il tempo impiegato dalla Terra per completare un'orbita completa rispetto alle stelle fisse. Questo periodo è leggermente più lungo, pari a circa 365 giorni, 6 ore, 9 minuti e 10 secondi.In sintesi, la Terra compie una rivoluzione completa attorno al Sole ogni anno, un evento che scandisce il passare del tempo e determina l'alternarsi delle stagioni.

Nella puntata 192 del Podcast di Basketcaffe Fuma e Dirk parlano della rivoluzione improvvisa ai Memphis Grizzlies con l'esonero di coach Jenkins, della pazzesca stagione degli Houston Rockets, tornati ai playoffs, e augurano buone vacanze ai Raptors e ai 76ers.

In this episode of The Beat Podcast, host Sandy Vance sits down with Jeff Taylor from Orbita to explore the intersection of operational efficiencies and enhancing patient experience and engagement in healthcare. At Orbita, the team believes these two areas should evolve in parallel, yet many health systems are struggling with isolated, one-off solutions that fail to address the broader challenges their organizations face.In this episode, they talk about:Orbita is transforming the patient experience and improving healthcare interactions.Empowering patients through more involvement in their healthcare, making them feel both more in control and cared for.Achieving up to a 30% reduction in staff inefficiencies by integrating Orbita into healthcare workflows.Breaking down AI concepts, including the difference between machine learning and generative AI, and the importance of safety in implementation.AI allows you to maximize your resources by allowing you to make decisions about where to allocate your team, time, energy, and money for optimal impact.A Little About Jeff:Jeff Taylor is the CEO of Orbita.ai, bringing over 20 years of leadership experience in healthcare IT and business solutions. His expertise in driving growth, operational excellence, and organizational transformation is key to leading Orbita through its next phase of innovation and expansion. Orbita powers virtual health assistants that help healthcare organizations engage patients, improve outcomes, and reduce costs.

Powieść Samanthy Harvey "Orbita" została nagrodzona Bookerem w 2024 roku. To historia, do której autorka bardzo dobrze się przygotowała. Chodź akcja dzieje się w kosmosie, to obserwacje i refleksje bohaterów dotyczą człowieka, życia i ziemskich spraw. W Dwójce o tej pozycji opowiedział Konrad Nowacki z wydawnictwa Wielka Litera.

Documental que sigue las historias más importantes del año 2024 a través de las impresionantes imágenes satelitales tomadas desde el espacio por diferentes satélites y que aportan una información única sobre nuestro planeta además de revelar las verdades ocultas detrás de algunos de los titulares del año 2024.

Il music business si è messo alle spalle la crisi di inizio anni 2000. Streaming e musica dal vivo sono più in salute che mai.

Il music business si è messo alle spalle la crisi di inizio anni 2000. Streaming e musica dal vivo sono più in salute che mai. 

Rasha Al-Lamee and Michael Foley sit down with Mamas Mamas to discuss data on an implantable coronary sinus reducer that can ease symptoms in patients with refractory angina.

Martin Mašek a jeho kometa (4:44 ) – Astronomie: Další zajímavosti o kometě C/2024 Y1 (15:14) – Kosmonautika v roce 2025, 3. část: Orbita, Měsíc a librační body (20:06)Všechny díly podcastu Planetárium můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

N Engl J Med 2023;389:2319-2330Background: Percutaneous coronary intervention (PCI) does not reduce mortality or myocardial infarction as seen in COURAGE, FAME 2, ISCHEMIA and ISCHEMIA-CKD. However, unblinded studies have indicated that revascularization may improve symptoms, which is a key factor in driving PCI decisions for many patients. ORBITA was the first blinded, placebo-controlled trial of PCI for stable angina and found no significant improvement in exercise time with PCI. The trial had a high use of anti-anginal medications, with an average of 3 medications per patient  pre-randomization. However, this level of medication use is not always achievable in clinical practice due to side effects and challenges with adherence.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.The ORBITA-2 trial sought to test the hypothesis that PCI improves symptoms in patients with stable angina who are not receiving background antianginal medications.Patients: Eligible patients had angina or angina equivalent, severe coronary stenosis of 70% or more in at least one coronary artery and evidence of ischemia on non-invasive testing or by invasive pressure wire assessment.Main exclusion criteria were acute coronary syndrome within 6 months, previous CABG, left main disease, chronic total occlusion of target vessel, and left ventricular ejection fraction of 35% or less.Baseline characteristics: The trial randomized 301 patients – 151 randomized to PCI and 150 to placebo PCI.The average age of patients was 64 years and 79% were men. Approximately 63% had hypertension, 28% had diabetes, 72% had hyperlipidemia, and 62% were current or previous smokers. Left ventricular systolic function was normal in 96% of the patients.Angina class based on the Canadian Cardiovascular Society (CCS) angina grade was 2 in 58% of the patients and 3 in 39%. Approximately 80% had single vessel disease, 17% had 2-vessel disease and 2% had 3-vessel disease. Left anterior descending coronary artery was the target vessel in 55% of the patients.Procedures: Patients initially underwent coronary angiogram and invasive physiologic assessment was performed in each vessel with 50% or more stenosis. Patients underwent the coronary angiography while wearing headphones with music playing for auditory isolation throughout the procedure. Patients who had evidence of ischemia in at least one territory were then randomized in a 1:1 ratio to PCI or placebo PCI. Patients were sedated until they were unresponsive to verbal and tactile stimuli. In the PCI group, all target vessels were treated during the index procedure. Patients in the placebo group did not receive intervention and were kept sedated for at least 15 minutes after randomization.The recovery room staff and all subsequent medical providers were unaware of the treatment assignments. The operator and research staff who were present during the randomization procedure had no further contact with the patients.Anti-anginal medications were stopped at enrollment. Antihypertensive medications that has antianginal properties were replaced with different agents.Patients were followed up for 12 weeks during which they reported daily angina symptoms using a smart phone application. New anti-anginal medications or increase in the dose of anti-anginal medications were also tracked. At the end of the 12 weeks, patients completed symptom and quality-of-life questionnaires, had an assessment of CCS class, and underwent a treadmill exercise test and dobutamine stress echocardiography. After all of these were completed, patients and medical staff were unblinded.Endpoints: The primary endpoint was an angina symptom score calculated based on the number of angina episodes that a patient reported on a given day and the number of units of antianginal medication prescribed on that day. In this score, each episode of angina on a particular day counts as 1 point for a maximum of 6 points per day (0 points given to no angina), and each unit of anti-anginal medications counts as 7 points (0 points given for no antianginal medications prescribed that day). In supplement table 3, authors provided what counted as one unit of anti-anginal medications. For example, atenolol 25 mg counted as 1 unit and amlodipine 2.5 mg counted as one unit.Secondary endpoints included frequency of angina, use of ant-anginal medications, exercise time on treadmill test and symptoms questionnaires.Analysis was performed based on the intention-to-treat principle. The estimated sample size to achieve 80% power at 0.05 alpha was 284 patients. This is based on assumed standard deviation of 6 angina symptom score units and a difference of 2 units between PCI and placebo.Results: Data were available on 99.7% of the total patient-days.Compared to placebo, PCI reduced the mean angina symptom score (2.9 vs 5.6, OR: 2.2, 95% CI: 1.4 - 3.5; p

For full review of the trials, please visit https://cardiologytrials.substack.com/ Get full access to Cardiology Trial's Substack at cardiologytrials.substack.com/subscribe

Surgical clearance, NICM assessment, dueling perspectives on PCI as first-line therapy for angina, GDMT in HFrEF are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. New ACC Peri-operative Guidelines Released ACC Guideline document https://www.jacc.org/doi/10.1016/j.jacc.2024.06.013 J Vasc Surg https://www.jvascsurg.org/article/S0741-5214(21)00335-9/fulltext McFalls and colleagues; CARP https://www.nejm.org/doi/full/10.1056/NEJMoa041905 II. NICM – We may be doing it wrong in Selecting ICDs JAMA Meta-analysis https://jamanetwork.com/journals/jama/fullarticle/2823869/ German CMR ICD Trial https://www.clinicaltrials.gov/study/NCT04558723 BRITISH CMR trial https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/britishusing-cmr-scar-as-risk-indication-tool-in-nicm-and-severe-lvsd/ III. When Should PCI be Used in Chronic Stable CAD?   Rajkumar and Al-Lamee; PCI First https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.124.011201   Boden and De Caterina; Meds First https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.124.011268 ORBITA 10.1016/S0140-6736(17)32714-9 ORBITA 2 trial https://www.nejm.org/doi/full/10.1056/NEJMoa2310610 IV. GDMT Underuse in HFrEF Greene and colleagues https://doi.org/10.1016/j.jchf.2024.08.002 DAPA HF https://www.nejm.org/doi/full/10.1056/NEJMoa1911303 RALES https://www.nejm.org/doi/full/10.1056/NEJM199909023411001 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

The Lancet Volume 391, Issue 10115, 6–12 January 2018, Pages 31-40Background:  For decades, cardiologists commonly used percutaneous coronary intervention (PCI) for the relief of angina. It made sense because PCI resulted in near complete resolution of blood flow through a stenosed vessel. The problem facing evidence-based clinicians was that no previous trial had compared PCI to a placebo (sham) procedure. Instead, previous trials had compared PCI (a procedure) to tablets. In the absence of blinding, a procedure will exert a larger placebo effect than tablets.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber.The Objective Randomized Blinded Investigation with optimal medical Therapy of Angioplasty in stable angina (ORBITA) trial was designed to assess the effect of PCI versus placebo on exercise time in patients with stable ischemic symptoms.ORBITA met ethical criteria because previous trials, primarily the COURAGE trial, had found that PCI in addition to medical therapy did not reduce hard outcomes, such as myocardial infarction or death due to cardiovascular causes, compared to medicine alone. In other words, PCI in patients with stable coronary artery disease was not a disease-modifying therapy; it was used to relieve symptoms.Patients:  Patients had to have single-vessel coronary artery disease (≥ 70% stenosis) that was appropriate for PCI and angina or equivalent symptoms. The authors published in the appendix pictures of every patient enrolled in the trial. Exclusion criteria included acute coronary syndrome, previous bypass surgery, left main stenosis, chronic total occlusions, severe valvular disease or left ventricular dysfunction, moderate or severe pulmonary hypertension, or life-expectancy less than 2 years.  Baseline Characteristics: The mean age of patients was 65 years. More than 79% were male. Almost 90% had normal left ventricular function. Canadian Cardiovascular Society class included about 60% with class 2 symptoms and nearly 40% with class 3 symptoms. Angina had been present for a mean of 9 months. Trial Procedures: ORBITA had two phases. First was a 6-week medical optimization phase wherein patients were optimally treated with medical therapy. They had a questionnaires, dobutamine stress echo, and a cardiopulmonary exercise test.  They then had the blinded procedure with either PCI or placebo.All PCI was done with drug-eluting stents. The procedure included measures to insure blinding, such as headphones during the procedure, sedation and a measure of hemodynamics such as fractional flow reserve. The second phase was a 6-week period of blanking in which patients underwent follow-up assessment. Testing procedures were similar to the pre-procedure protocol.At all times, the staff were blinded to the procedural data. This included procedural details as well as post-procedural assessment. The recovery staff were well rehearsed in their role of maintenance of blinding. Patients and subsequent medical caregivers were also blinded to treatment allocation. The study physicians present during the procedure had no further contact with the patient during the study.By the time of randomization, in the PCI group, 103 (98%) of 105 patients were taking aspirin, 103 (98%) were taking a second antiplatelet, and 99 (94%) were taking a statin, compared to 93 (98%), 94 (99%), and 91 (96%) of 95 patients, respectively, in the placebo group. At the same timepoint, in the whole study population, 156 (78%) of 200 patients were taking β blockers and 182 (91%) were taking calcium channel antagonists.The mean number of antianginal medications in the PCI group was 0·90 (SD 0·8) at enrollment, 2·8 (1·2) at pre-randomization, and 2·9 (1·1) at follow-up, compared to the placebo group in which the mean number of medications was 1·0 (0·9; p=0·357), 3·1 (0·9; p=0·097), and 2·9 (1·1; p=0·891), respectively.Endpoints: The primary endpoint of ORBITA was the difference between PCI and placebo groups in the change in treadmill exercise time. The power calculation relied on previous trials wherein PCI had resulted in a 48-55 second increase in exercise time over medicine. ORBITA authors designed the trial to detect a 30 second increase in exercise time.They estimated that a sample size of 100 patients per group had more than 80% power to detect a between-group difference in the increment of exercise duration of 30 seconds, at the 5% significance level, using the two-sample t test of the difference between groups. This calculation assumed a between-patient standard deviation of change in exercise time of 75 s. Since there had been no previous placebo-controlled trials of PCI, the authors initially allowed for a one-third dropout rate in the 6-week period of medical optimization between enrollment and randomization and therefore planned to enroll 300 patients. But the dropout rate was much lower, so only 230 patients had to be enrolled. The primary endpoint was continuous, and it was calculated as a difference between groups. They also measured secondary endpoints, including measures of angina severity and quality of life.Results: A total of 368 patients were screened for eligibility, and 200 were randomly assigned. Most were excluded from randomization because they declined to participate. There were 105 allocated to PCI (all but one had PCI) and 95 to placebo (4 patients had PCI due to a procedural complication).Across all patients, the mean area stenosis by quantitative coronary angiography was 84·4% (SD 10·2), mean FFR was 0·69 (0·16), and mean iFR was 0·76 (0·22). 57 (29%) patients had FFR greater than 0·80 and 64 (32%) had iFR greater than 0·89.The median length of stent implanted was 24 mm (IQR 18–33). After PCI, the mean FFR improved to 0·90 (SD 0·06; p

ORBITA2-Symptoms: The Symptom-Stratified Analysis of ORBITA-2

Quale fattore è alla base del dominio di Pecco ad Assen? Sono tante le Ducati, altre tre 2024 e pure le 23 che qualcuno riesce a sfruttare a dovere. Allora vediamo quanto giocano, per il successo, le qualità del campione del mondo e quelle della sua super squadra.  Assen resta l'università della moto? Sì, e mostra tante realtà: l'Aprilia che funziona molto bene ma raccoglie poco, la KTM che ha ancora qualche area da sistemare, la Yamaha che resta un passo indietro (ma si rinforza dal 2025 con Pramac), la Honda che brancola del buio... La penalità a Marquez? Correre sul filo della pressione minima ha condizionato la sua gara. Marc pareva da podio, ha guidato "sulle uova"e la penalizzazione di ben 16" (per 0,001 bar...) lo ha messo fuori gioco. Errore suo o della squadra? Forse, secondo qualcuno, sarebbe da sanzionare il regolamento... Chiariremo la regola e indagheremo sulle varie polemiche. Poi le altre due gare, gli aggiornamenti sulle condizioni di Rins e di Espargaro, infine i pronostici per la Germania. Perché si corre subito al Sachsenring e lo Zam è già in sella alla sua moto...

Coronary Sinus Reducer for the Treatment of Refractory Angina: A Randomized, Placebo-Controlled Trial (ORBITA-COSMIC)

Polska firma PIAP Space, lider w dziedzinie robotyki kosmicznej, zakończyła projekt ORBITA, którego celem jest zwiększenie użyteczności i efektywności obsługi satelitów przez wprowadzenie chwytaków przeznaczonych do użycia na manipulatorach robotycznych na orbicie. Zaproponowane w ramach programu rozwiązanie umożliwi prowadzenie regularnych misji konserwacyjnych i naprawczych w trudnym środowisku kosmicznym. To klucz do oszczędności i szansa przedłużania czasu działania satelitów albo strącania z orbity kosmicznych śmieci. Jak mówi RMF FM kierownik projektu ORBITA Andrzej Jakubiec, PIAP Space uczestniczy w finansowanym przez Komisję Europejską projekcie EROSS IOD, który w 2027 roku ma pokazać możliwości serwisowe na orbicie. Istotną rolę będzie miał do wykonania opracowany przez Polaków chwytak LARIS.

ACC.24: ORBITA-COSMIC

AI has seen rapid adoption in health systems, but are we ready for it? In this episode, hosts Reed Smith and Chris Boyer discuss the challenges with adopting federal regulation on AI and how local organizations can begin developing an AI governance framework. Patty Riskind, CEO of Orbita, joins to share her perspectives on responsible AI adoption in health systems.   Mentions from the Show: Healthcare startups are rushing to sell AI to hospital systems. But a new survey suggests many simply aren't ready for it. Artificial intelligence is making critical health care decisions. The sheriff is MIA. 5 best practices for AI governance: Building a culture for responsible - Fast Company Building an AI Governance Framework Patty Riskind on LinkedIn https://orbita.ai/ Learn more about your ad choices. Visit megaphone.fm/adchoices

This Ukrainian ghost town wasn't as abandoned as I thought by RedHotOwl 0:00 - 15:53 Black Cab by Christopher Haynes 15:53 - 41:38 Author Credits: https://www.reddit.com/r/nosleep/comments/kn2bbu/this_ukrainian_ghost_town_wasnt_as_abandoned_as_i/ https://www.reddit.com/user/RedHotOwl/ https://www.creepypasta.com/black-cab/ --- Send in a voice message: https://podcasters.spotify.com/pod/show/themisterdavis/message

As many of you know, I have long argued (unsuccessfully until now) for a placebo-controlled trial of AF ablation. One group gets the ablation; the other gets a placebo or sham procedure. This way we can sort out the placebo-resistant effect of the ablation. Finally, here is the first report of one. Dr. Malcolm Finlay is an electrophysiologist at St Bartholomew hospital in London UK and primary investigator of the study. They recently published their feasibility study for AF ablation vs placebo. The American Heart Journal published the pilot study of 20 patients. Finlay and colleagues call it the ORBITA AF trial. But it's important to note that this was done separate from the ORBITA investigators at Imperial College. The larger study will have a different name. Here is a copy and paste:Twenty patients with PersAF (duration

In this week's Parallax, Dr Ankur Kalra welcomes back Dr Sukhjinder Nijjer for their much-anticipated annual review of advancements in cardiovascular medicine that defined the year 2023. Dr Nijjer, a Consultant Cardiologist in the UK, serves as the President of the Royal Society of Medicine and is an Honorary Senior Clinical Lecturer at Imperial College London. Drs Kalra and Nijjer share their perspectives and experiences, offering valuable insights, practical tips and considerations when interpreting this year's most impactful trials: • ORBITA-2 (AHA Scientific Sessions): PCI for stable angina • FIRE (ESC Congress): Functional versus culprit-only revascularization in elderly patients with myocardial infarction and multivessel disease • DAPA-MI (AHA Scientific Sessions): SGLT2i in MI without diabetes or heart failure • ILUMIEN IV (ESC Congress): OCT vs angiography-guided PCI • OCTOBER (ESC Congress): OCT or Angiography Guidance for PCI in Complex Bifurcation Lesions • ARTESIA (ESC Congress): Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation • SELECT (AHA Scientific Sessions): Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes What are the most impactful cardiovascular trials of 2023? How do Dr Kalra and Dr Nijjer integrate the latest information into their daily practices?

For this year's review, Bob Harrington and Mike Gibson revisit the major cardiology conferences -- from ACC in New Orleans to AHA in Philly. This podcast is intended for healthcare professionals only. To read a transcript or to comment, visit: https://www.medscape.com/author/bob-harrington ACC 2023 Top Trials - Bempedoic Acid Cuts CV Events in Statin-Intolerant Patients: CLEAR Outcomes https://www.medscape.com/viewarticle/989100 - Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients - Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616 https://www.jacc.org/doi/10.1016/j.jacc.2023.02.018 ACC/WCC 2023 Collection Page https://www.medscape.com/viewcollection/36966 ESC 2023 Top Trials - Wegovy Scores HFpEF Benefits in People With Obesity https://www.medscape.com/viewarticle/995844 - Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity https://www.nejm.org/doi/full/10.1056/NEJMoa2306963 - Acoramidis Shows Encouraging Results in ATTR Cardiomyopathy https://www.medscape.com/viewarticle/995883 ESC 2023 Collection Page https://www.medscape.com/viewcollection/36988 AHA 2023 Top Trials - Semaglutide 'A New Pathway' to CVD Risk Reduction: SELECT https://www.medscape.com/viewarticle/998373 - Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes https://www.nejm.org/doi/full/10.1056/NEJMoa2307563 - Bariatric Surgery is Associated With Improved Coronary Microvascular Function and Cardiorespiratory Fitness in Patients With Ischemia and Non-Obstructive Coronary Arteries https://www.ahajournals.org/doi/10.1161/circ.148.suppl_1.18949 - Angioplasty Finally Proven Beneficial in Stable Angina: ORBITA-2 https://www.medscape.com/s/viewarticle/998375 - A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable Angina https://www.nejm.org/doi/full/10.1056/NEJMoa2310610 - Impressive Bleeding Profile With Factor XI Inhibitor in AF: AZALEA https://www.medscape.com/viewarticle/998418 - Promising First Results With DNA Editing to Lower LDL https://www.medscape.com/s/viewarticle/998719 - Single Injection Reduces Blood Pressure for 6 Months: KARDIA-1 https://www.medscape.com/viewarticle/998666 AHA 2023 Collection Page https://www.medscape.com/viewcollection/37277 Other Mentions - N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects https://www.nejm.org/doi/full/10.1056/NEJMc2031173 - Rimonabant: From RIO to Ban https://doi.org/10.1155%2F2011%2F432607 - Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial https://doi.org/10.1016/S0140-6736(17)32714-9 - Asundexian Phase 3 AF Study Halted for Lack of Efficacy https://www.medscape.com/viewarticle/998665 - Challenges in the Design and Interpretation of Noninferiority Trials https://www.nejm.org/doi/full/10.1056/nejmra1510063 - Milvexian for the Prevention of Venous Thromboembolism https://www.nejm.org/doi/full/10.1056/NEJMoa2113194 You may also like: Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine Hear John Mandrola, MD's summary and perspective on the top cardiology news each week, on This Week in Cardiology https://www.medscape.com/twic Questions or feedback, please contact news@medscape.net

TLM - Em 2016 los astrónomos descubrieron un objeto que, habiendo salido de la Luna, se ha convertido en un "cuasi satélite natural de la Tierra". En este episodio nos ocupamos de los "otros" satélites de la Tierra. Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

AHA23 Congress Coverage: PCI for Stable Angina (ORBITA-2 Trial)

This episode focuses on the impact of Artificial Intelligence in the healthcare sector. We  explore how AI is improving patient experiences and streamlining healthcare processes. My guest, Patty Riskind, CEO of Orbita,  discusses her journey in the healthcare industry and the experiences that have influenced her leadership approach.Patty explains the role of generative and conversational AI in healthcare, examining its contribution to more empathetic patient interactions and its role in reducing administrative tasks for healthcare providers. We discuss advancements in AI-driven product development, particularly in speeding up chatbot deployment. The capabilities of virtual healthcare assistants, including appointment scheduling and post-visit follow-ups, are also covered.Support the showHost David E. Williams is president of healthcare strategy consulting firm Health Business Group. Produced by Dafna Williams.

An AHA Recap: SELECT, ORBITA2, and ARTESIA are the trials John Mandrola, MD, reviews in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic American Heart Association 2023 on theHeart.org | Medscape Cardiology https://www.medscape.com/viewcollection/37277 I. SELECT Trial Semaglutide 'A New Pathway' to CVD Risk Reduction: SELECT https://www.medscape.com/viewarticle/998373 Positive Results From SELECT Begins a New Era in Cardiology https://www.medscape.com/viewarticle/998217 Is It Time for Cardiologists to Treat Obesity? https://www.medscape.com/viewarticle/998391 - SELECT trial https://www.nejm.org/doi/full/10.1056/NEJMoa2307563 - SUSTAIN 6 https://www.nejm.org/doi/full/10.1056/nejmoa1607141 II. ORBITA 2 Angioplasty Finally Proven Beneficial in Stable Angina: ORBITA-2 https://www.medscape.com/s/viewarticle/998375 ORBITA-2 Saves Interventional Cardiology and Challenges Current Guidance https://www.medscape.com/viewarticle/998213 PCI, the Antianginal 'Pill': ORBITA-2 in Detail https://www.medscape.com/viewarticle/997777 - ORBITA-2; NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2310610 - ORBITA 1 https://doi.org/10.1016/S0140-6736(17)32714-9 III. ARTESIA Apixaban Cuts Stroke but Ups Bleeding in Subclinical AF: ARTESIA https://www.medscape.com/viewarticle/998379 Sadly, ARTESIA Doesn't Answer a Common Question in Cardiology https://www.medscape.com/viewarticle/998215 - NOAH https://www.nejm.org/doi/full/10.1056/NEJMoa2303062 - ARTESIA https://www.nejm.org/doi/10.1056/NEJMoa2310234 - AVERROES https://www.nejm.org/doi/full/10.1056/NEJMoa1007432 - McIntyre Meta-analysis https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.067512 - TRENDS https://www.ahajournals.org/doi/10.1161/circep.109.849638 - ASSERT https://doi.org/10.1093/eurheartj/ehx042 You may also like: Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

S1E11: Join host Jared Johnson and guest Patty Riskind, CEO of Orbita as they discuss how to "slay the dragons of doubt" about healthcare chatbots and virtual assistants. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio.” Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen